

Inventor: Biaoyang Lin
Serial No.: 09/821,812
Filed: March 28, 2001
Page 2

RECEIVED

DEC 04 2003

TECH CENTER 1600/2900

changes made relative to the immediate prior version by
underlining of added text and bracketing of deleted text.

Remarks/arguments begin on page 5 of this paper.

CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS

Please cancel claims 17 to 23 and claim 33 herein.

1 to 23. Canceled.

24. (Currently amended) [A substantially pure] An
isolated ARP3 polypeptide, comprising an amino acid sequence
having at least 45% amino acid identity with residues 1 to 537
of SEQ ID NO:5.

25. (Currently amended) [The substantially pure] The
isolated ARP3 polypeptide of claim 24, comprising the amino acid
sequence shown as SEQ ID NO:5.

26. (Currently amended) [The substantially pure] The
isolated ARP3 polypeptide fragment, comprising at least [eight]
ten contiguous amino acids of SEQ ID NO:5.

27. (Withdrawn) A binding agent, comprising a
molecule that selectively binds an ARP3 polypeptide having at
least 45% amino acid identity with SEQ ID NO:5.

28. (Withdrawn) The binding agent of claim 27,
wherein said binding agent is an antibody.



29. (Withdrawn) A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) contacting a specimen from said individual with the binding agent of claim 27;

(b) determining a test expression level of ARP3 polypeptide in said specimen; and

(c) comparing said test expression level to a non-neoplastic control expression level of ARP3 polypeptide,

wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.

30. (Withdrawn) The method of claim 29, wherein said specimen comprises prostate tissue.

31. (Withdrawn) The method of claim 29, wherein said specimen is selected from the group consisting of blood, serum, urine and semen.

32. (Withdrawn) The method of claim 29, wherein said binding agent that selectively binds said ARP3 polypeptide is an antibody.

33. Canceled.

34. (New) The isolated ARP3 polypeptide of claim 24, comprising an amino acid sequence having at least 65% amino acid identity with residues 1 to 538 of SEQ ID NO:5.

35. (New) The isolated ARP3 polypeptide of claim 24, comprising an amino acid sequence having at least 75% amino acid identity with residues 1 to 538 of SEQ ID NO:5.

36. (New) The isolated ARP3 polypeptide of claim 24, comprising an amino acid sequence having at least 85% amino acid identity with residues 1 to 538 of SEQ ID NO:5.

37. (New) The isolated ARP3 polypeptide of claim 24, comprising an amino acid sequence having at least 95% amino acid identity with residues 1 to 538 of SEQ ID NO:5.

38. (New) An isolated ARP3 polypeptide, comprising the amino acid sequence shown as SEQ ID NO: 5 with substitution of one or more conservative amino acid residues.